Cognitive Enhancement as a Target for Cocaine Pharmacotherapy

Conditions

Addiction

What is the purpose of this trial?

Specific Aim #1: To determine if galantamine (8 or 16 mg/day) is more effective than placebo in reducing cocaine use as measured by cocaine urine results and self-report days of use.

Specific Aim # 2: To determine if galantamine (8 or 16 mg/day) is more effective than placebo in improving attention, assessed with the Rapid Visual Information Processing (RVIP) and the Simple Reaction Time (SRT) tests Specific Aim # 3: To determine if improvement in attention during the first four weeks of treatment will mediate galantamine's efficacy in reducing cocaine use.



Participation Guidelines

Age:
18 Years - 60 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
National Institute on Drug Abuse (NIDA)
Yale University
Dates:
September 2011
Last Updated:
June 13, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01531153